BIOGEN INC. Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax
BIOGEN INC. (BIIB) reported Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax of $760.00 thousand for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-04.
Discontinued › Expense Statement › Income Tax
us-gaap:OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax · last filed 2015-02-04
- BIOGEN INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2013-03-31 was $1.60M.
- BIOGEN INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2011-03-31 was $2.00M, a 33.33% decline year-over-year.
- BIOGEN INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for the quarter ending 2010-03-31 was $3.00M.
- BIOGEN INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2014 was $760.00K, a 55.84% decline from fiscal 2013.
- BIOGEN INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2013 was $1.72M, a 23.28% increase from fiscal 2012.
- BIOGEN INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2012 was $1.40M, a 61.72% decline from fiscal 2011.
- BIOGEN INC. other comprehensive income (loss), unrealized gain (loss) on derivatives arising during period, tax for fiscal 2011 was $3.65M, a 187.62% increase from fiscal 2010.
| Period end | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 3 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 12 month | Other Comprehensive Income (Loss), Unrealized Gain (Loss) on Derivatives Arising During Period, Tax 12 month as first filed |
|---|---|---|---|
| 2014-12-31 | $760.00K 10-K · filed 2015-02-04 | ||
| 2013-12-31 | $1.72M 10-K · filed 2015-02-04 | ||
| 2013-03-31 | $1.60M 10-Q · filed 2013-04-25 | ||
| 2012-12-31 | $1.40M 10-K · filed 2015-02-04 | ||
| 2011-12-31 | $3.65M 10-K · filed 2013-02-05 | ||
| 2011-03-31 | $2.00M 10-Q · filed 2011-04-21 | ||
| 2010-12-31 | $1.27M 10-K · filed 2013-02-05 | ||
| 2010-03-31 | $3.00M 10-Q · filed 2011-04-21 | ||
| 2009-12-31 | $254.00K 10-K · filed 2012-02-03 | -$3.58M 10-K · filed 2010-02-09 | |
| 2008-12-31 | $1.52M 10-K · filed 2010-02-09 | ||
| 2007-12-31 | $2.26M 10-K · filed 2010-02-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |